These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23656755)

  • 21. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
    Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
    Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
    Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
    J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
    Stallings RL; Nair P; Maris JM; Catchpoole D; McDermott M; O'Meara A; Breatnach F
    Cancer Res; 2006 Apr; 66(7):3673-80. PubMed ID: 16585193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
    He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
    Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
    Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
    Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
    Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
    PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q.
    Simon T; Spitz R; Hero B; Berthold F; Faldum A
    Cancer Lett; 2006 Jun; 237(2):215-22. PubMed ID: 16019135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
    Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
    J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
    Guimier A; Ferrand S; Pierron G; Couturier J; Janoueix-Lerosey I; Combaret V; Mosseri V; Thebaud E; Gambart M; Plantaz D; Marabelle A; Coze C; Rialland X; Fasola S; Lapouble E; Fréneaux P; Peuchmaur M; Michon J; Delattre O; Schleiermacher G
    PLoS One; 2014; 9(7):e101990. PubMed ID: 25013904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
    Guo C; White PS; Hogarty MD; Brodeur GM; Gerbing R; Stram DO; Maris JM
    Med Pediatr Oncol; 2000 Dec; 35(6):544-6. PubMed ID: 11107113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
    Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
    Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
    Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
    Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma.
    Ooi WF; Re A; Sidarovich V; Canella V; Arseni N; Adami V; Guarguaglini G; Giubettini M; Scaruffi P; Stigliani S; Lavia P; Tonini GP; Quattrone A
    Genes Chromosomes Cancer; 2012 Jun; 51(6):545-56. PubMed ID: 22337647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.